Antibody Drug Conjugate Market 2025 to 2033 Growth Opportunities
Antibody-drug conjugates (ADCs) are specialized biopharmaceutical medications that combine monoclonal antibodies with highly potent anti-cancer agents. The antibodies are designed to recognize specific surface antigens on tumor cells, while the anti-cancer agents are linked to the antibodies through a chemical linker.